Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Tuebingen – page 38

607 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
607
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

607 trials in Tuebingen

Open in trial search

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Chronic spontaneous urticaria

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Chronic graft versus host disease

Not recruiting

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Acute myeloid leukaemia

Not recruiting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Effectiveness of LASN01 for Patients with Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lasn01
  • Sponsor:Lassen Therapeutics 1 Inc.

Skin ulcer

Not recruiting

Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells
  • Sponsor:Rheacell GmbH & Co. KG

Study on Amantadine Hemisulfate for Patients with Unresponsive Wakefulness Syndrome in Intensive and Intermediate Care Units

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hemisulfate
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on cutaneous lupus erythematosus and psoriatic arthritis, evaluating novel therapeutic approaches for managing chronic inflammatory conditions.

  • Lupus skin manifestations
  • Joint inflammation
  • Autoimmune responses

Studies aim to assess new treatment options for improving patient outcomes and quality of life.

02 Oncology Research

Comprehensive studies on various cancer types, including metastatic prostate cancer and basal cell carcinoma, exploring innovative treatment combinations.

  • Advanced cancer therapies
  • Pediatric liver tumors
  • Targeted treatments

Research focuses on improving survival rates and developing more effective treatment strategies.

03 Neurological Disorders

Groundbreaking research in multiple system atrophy and seizure disorders, investigating new therapeutic approaches for complex neurological conditions.

  • Brain function disorders
  • Movement disorders
  • Epilepsy management

Clinical trials aim to enhance treatment options for patients with challenging neurological conditions.

04 Ophthalmology Studies

Advanced research in eye disorders, including Leber congenital amaurosis and geographic atrophy, focusing on innovative treatment approaches.

  • Retinal diseases
  • Visual function
  • Gene therapy

Trials aim to preserve and improve vision in patients with rare and progressive eye conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.